- XORTX Therapeutics (XRTX) announced positive topline results from the first of its three part Pharmacokinetics Bridging Study – XRX-OXY-101
- The study showed a substantial increase in oral bioavailability of two versions of XORTX’s proprietary oxypurinol formulation compared to a control formulation
- XORTX is a clinical-stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease
- XORTX Therapeutics Inc. (XRTX) was up 56.67 per cent on the day, trading at C$2.35
XORTX Therapeutics (XRTX) announced positive topline results from the first of its three part Pharmacokinetics Bridging Study – XRX-OXY-101.
The study showed a substantial increase in oral bioavailability of two versions of XORTX’s proprietary oxypurinol formulation compared to a control formulation.
Accompanying the improved bioavailability findings in the trial was a clean safety and pharmacologic profile with no drug related adverse or serious adverse events related to oral administration of oxypurinol.
XORTX CEO, Allen Davidoff stated that the successful completion of Part 1 of the XRX-OXY-101 study provided important knowledge for selecting the clinical dose and formulation for future oral dosing in our upcoming phase 3 registration trial.
“Pharmacokinetic modeling of this data will provide additional information to guide decision making as we plan and execute development of the XRx-008 program clinical and commercial development. We look forward to the initiation of dosing of Part 2 of the XRX-OXY-101 this week.”
XORTX is a clinical-stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease.
XORTX Therapeutics Inc. was up 56.67 per cent on the day, trading at C$2.35.